Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Biosimilar User Fee Agreement Offers FDA Funding Boost, Fee Structure Overhaul

Executive Summary

BsUFA revenue amounts and fees will be separated from PDUFA and relative contribution of each fee type to the overall pot will change; user fee revenue target for program's first year is $45m.


Related Content

Biosimilars In 2017: Crowded US FDA Review Queue, Key Legal Decisions
User Fees For FY 2017 Make Sponsors Happy, Manufacturers Sad
Amgen's Humira Biosimilar Gains Nod From Panel Perplexed By Regulatory Pathway
Biosimilar User Fee Reboot: Resource Challenges Make FDA Eye New Structure
Biosimilar User Fee Collections Rise, But Little Spent On Program Costs
Biosimilars Reviews Could Be Extended Two Months In BsUFA II
Biosimilar User Fee Talks Begin With Industry Negotiating Amongst Itself
Pending Biosimilars
Biosimilars Program Could 'Explode,' Woodcock Warns Congress
Biosimilar User Fees Could Be Raised Significantly In Renewal Talks


Related Companies